Immunotherapy Trial Design
Future validation should prospectively test the macrophage M0 signature in neoadjuvant immunotherapy trials. The study positions MRI-based immune profiling as a potential enrichment tool for neoadjuvant immunotherapy trials. Candidate macr…
1 sources - 4 claims
Future validation should prospectively test the macrophage M0 signature in neoadjuvant immunotherapy trials. The study positions MRI-based immune profiling as a potential enrichment tool for neoadjuvant immunotherapy trials. Candidate macrophage-directed approaches include CSF-1/CSF1R inhibition, TLR agonists, oncolytic viral therapies, checkpoint inhibitors, cytokine therapies, and anti-CD47 therapy. Macrophage M0 results were discussed in relation to therapies that target or reprogram macrophage biology.